Conor Barry
YOU?
Author Swipe
View article: The Dental Oncology Complication that Wouldn’t go Away
The Dental Oncology Complication that Wouldn’t go Away Open
Background: Bone modifying agents are used throughout cancer care and their utilisation can optimise advanced stage cancer cases with bone metastases, by reducing skeletal-related events, treatment-induced bone loss and treatment hypercalc…
View article: Supplemental methods and tables from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
Supplemental methods and tables from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies Open
Supplemental methods and tables
View article: Data from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
Data from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies Open
Despite the many advances in the treatment of hematologic malignancies over the past decade, outcomes in refractory lymphomas remain poor. One potential strategy in this patient population is the specific targeting of IL2R-α (CD25), which …
View article: Supplemental Figure 5 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
Supplemental Figure 5 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies Open
In vivo efficacy in Karpas disseminated models. Kaplan Meier survival plots of disseminated Karpas 299 models
View article: Data from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
Data from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies Open
Despite the many advances in the treatment of hematologic malignancies over the past decade, outcomes in refractory lymphomas remain poor. One potential strategy in this patient population is the specific targeting of IL2R-α (CD25), which …
View article: Supplemental Figure 2 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
Supplemental Figure 2 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies Open
MTS assays on cell lines after treatment with ADCT-301, Non-binding ADC and naked antibody, HuMax-TAC
View article: Supplemental Figure 4 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
Supplemental Figure 4 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies Open
In vivo efficacy in Karpas 299 subcutaneous models. Kaplan Meier survival plots of subcutaneous models in Figures 5A and 5B
View article: Supplemental methods and tables from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
Supplemental methods and tables from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies Open
Supplemental methods and tables
View article: Supplemental Figure 3 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
Supplemental Figure 3 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies Open
Comet assay on CD25-negative Daudi cells after ADCT-301 and SG3199 treatment
View article: Supplemental Figure 6 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
Supplemental Figure 6 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies Open
In vivo efficacy in Ramos disseminated model. Kaplan Meier survival plots of disseminated CD25-negative Ramos model
View article: Supplemental Figure 4 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
Supplemental Figure 4 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies Open
In vivo efficacy in Karpas 299 subcutaneous models. Kaplan Meier survival plots of subcutaneous models in Figures 5A and 5B
View article: Supplemental Figure 1 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
Supplemental Figure 1 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies Open
DAR determination by SEC, RPLC and HIC
View article: Supplemental Figure 3 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
Supplemental Figure 3 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies Open
Comet assay on CD25-negative Daudi cells after ADCT-301 and SG3199 treatment
View article: Supplemental Figure 7 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
Supplemental Figure 7 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies Open
In vivo PBMC DNA cross-linking. DNA cross-linking as measured in CD25-negative PBMCs from SCID mice treated with ADCT-301
View article: Supplemental Figure 2 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
Supplemental Figure 2 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies Open
MTS assays on cell lines after treatment with ADCT-301, Non-binding ADC and naked antibody, HuMax-TAC
View article: Supplemental Figure 5 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
Supplemental Figure 5 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies Open
In vivo efficacy in Karpas disseminated models. Kaplan Meier survival plots of disseminated Karpas 299 models
View article: Supplemental Figure 7 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
Supplemental Figure 7 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies Open
In vivo PBMC DNA cross-linking. DNA cross-linking as measured in CD25-negative PBMCs from SCID mice treated with ADCT-301
View article: Supplemental Figure 1 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
Supplemental Figure 1 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies Open
DAR determination by SEC, RPLC and HIC
View article: Supplemental Figure 6 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
Supplemental Figure 6 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies Open
In vivo efficacy in Ramos disseminated model. Kaplan Meier survival plots of disseminated CD25-negative Ramos model
View article: Outcomes of Preoperative Testing for SARS-CoV-2 in Otolaryngology Surgery during the Pandemic
Outcomes of Preoperative Testing for SARS-CoV-2 in Otolaryngology Surgery during the Pandemic Open
Objective: Preoperative testing for COVID-19 has become widely established to avoid inadvertent surgery on patients with COVID-19 and prevent hospital outbreaks, however, there is limited evidence underpinning new protocols. We wished to s…
View article: Head and neck reconstruction in the SARS-CoV-2 pandemic era: outcomes and lessons learned
Head and neck reconstruction in the SARS-CoV-2 pandemic era: outcomes and lessons learned Open
The COVID-19 pandemic is having a significant impact on the provision of non-COVID-19 related clinical services. Early recommendations for head and neck reconstructive surgery were based on guidance from expert groups, advocating de-intens…
View article: Pre‐operative testing for <scp>SARS‐CoV</scp>‐2 and outcomes in otolaryngology surgery during the pandemic: A <scp>multi‐center</scp> experience
Pre‐operative testing for <span>SARS‐CoV</span>‐2 and outcomes in otolaryngology surgery during the pandemic: A <span>multi‐center</span> experience Open
Introduction Preoperative testing for COVID‐19 has become widely established to avoid inadvertent surgery on patients with COVID‐19 and prevent hospital outbreaks. Methods A prospective cross sectional study was carried out in two universi…